Funded Tech Companies
Rewind Therapeutics
Researching who provided funding to Rewind Therapeutics? Boehringer Ingelheim Venture Fund, KU Leuven and PMV joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
Rewind Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Gaston Geenslaan 2
Leuven, 3001
Belgium
Leuven, 3001
Belgium
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. A common feature of these illnesses is the loss of the natural myelin sheath, a cover protecting and nurturing the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or even curing these diseases. Rewind´s team has extensive research and development expertise and a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, Axxam, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
1/25/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anja Harmeier
Chief Financial Officer
Christophe Vaeck
Chief Scientific Officer
Irene Knuesel
Company Investors
- Boehringer Ingelheim Venture Fund
- KU Leuven
- PMV
- Gemma Frisius Fund
- M Ventures
- Sunstone Life Science Ventures
Browse more funded tech companies:
Share this article
About Our VC & M&A Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs